[Progress in novel biomarkers of anti-tuberculosis drug-induced liver injury].
Zhonghua Jie He He Hu Xi Za Zhi
; 47(5): 469-474, 2024 May 12.
Article
em Zh
| MEDLINE
| ID: mdl-38706071
ABSTRACT
Anti-tuberculosis drug-induced liver injury(ATB-DILI) is the most common adverse reaction during anti-tuberculosis therapy in tuberculosis patients. At present, the diagnosis of ATB-DILI is mainly based on traditional biomarkers such as transaminases, but these indicators have low specificity for liver toxicity, they cannot explain the mechanism of liver injury and the early onset of ATB-DILI. Based on the prediction of disease severity, treatment and prevention, this paper described the current potential biomarkers of ATB-DILI.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores
/
Doença Hepática Induzida por Substâncias e Drogas
/
Antituberculosos
Limite:
Humans
Idioma:
Zh
Revista:
Zhonghua Jie He He Hu Xi Za Zhi
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China